The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies.
 
Arkadiusz Z. Dudek
Leadership - IGF Oncology; Martell diagnostic; Squarex Pharma; TTC Oncology
Stock and Other Ownership Interests - IGF Oncology; Martell diagnostic; Squarex Pharma; TTC Oncology
Patents, Royalties, Other Intellectual Property - IGF Oncology
 
Dejan Juric
Consulting or Advisory Role - Eisai; EMD Serono; Genentech; Ipsen; MapKure; Novartis; Petra Pharma; Syros Pharmaceuticals; Vibliome Therapeutics
Research Funding - Amgen (Inst); Eisai (Inst); EMD Serono (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Placon (Inst); Syros Pharmaceuticals (Inst); Takeda (Inst); Takeda (Inst)
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; AstraZeneca; Bayer; Bristol-Myers Squibb; G1 Therapeutics; Ipsen; Seagen; Takeda
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Regeneron (Inst); Seagen (Inst); Symphogen (Inst); Takeda (Inst); Tesaro (Inst); United Therapeutics (Inst)
 
Erlene Kuizon Seymour
Employment - Flatiron Health
Consulting or Advisory Role - Garner Health; Janssen Oncology; Karyopharm Therapeutics
Research Funding - Karyopharm Therapeutics
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Ellipses Pharma; Ionctura; Kelun; Lilly; Merck Sharp & Dohme; Molecular Partners; Novartis; NovellusDx; Orion; Peptomyc; Pfizer; Roche/Genentech; SERVIER; Spectrum Pharmaceuticals
Research Funding - Bayer; BioAtla; Blueprint Medicines; CytomX Therapeutics; Genmab; GlaxoSmithKline; Ipsen; Kelun; Novartis; Pfizer; Spectrum Pharmaceuticals; Symphogen; Takeda/Millennium; Tocagen
Travel, Accommodations, Expenses - Cancer Core Europe; Department of Defense; ESMO; Huntsman Cancer Institute; Karolinska Cancer Institute; King Abdullah International Medical Research Center; Louisiana State University; Molecular Partners
Other Relationship - Chinese University of Hong Kong; Elsevier; European Journal of Cancer; GlaxoSmithKline; SOLTI; Vall d'Hebron University Hospital Institute of Oncology
 
Bingxia Wang
No Relationships to Disclose
 
Dennis Huszar
Employment - Millennium
 
Allison J. Berger
Employment - Millennium
 
Sharon Friedlander
Employment - Millennium
 
Alejandro Gomez-Pinillos
Employment - Millennium
 
Igor Proscurshim
Employment - Millennium
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Pfizer; Sanofi
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Gan & Lee (Inst); GlaxoSmithKline (Inst); Glyconex (Inst); Immunocore (Inst); Intensity Therapeutics (Inst); Iovance Biotherapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Navire (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Seagen (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sumitomo Group (Inst); Takeda (Inst); Targovax (Inst)
(OPTIONAL) Uncompensated Relationships - Takeda